| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
,
OSCAR A. KLETZKY,
CAROLE A. SPENCER and
JOHN T. NICOLOFF
Division of Endocrinology, Departments of Medicine and Obstetrics and Gynecology, University of Southern California School of Medicine Los Angeles, California 90033
Address requests for reprints to: Elaine M. Kaptein, M.D., University of Southern California School of Medicine, Room 18–621, 2025 Zonal Avenue, Los Angeles, California 90033.
The influence of a 48-h dopamine (DA) infusion (5–7.5 µg/kg-min) on serum PRL, TSH, LH, FSH, and GH values was determined in six normal adult males. Sustained suppression of serum PRL to 78% (P < 0.01) below baseline levels during DA was followed by an acute rebound of 319% (P < 0.01) 4 h after stopping DA. Similarly, TSH decreased by 44% during DA but had a more gradual and sustained rebound of 41% (P < 0.01) over a 36-h period. While both serum LH and FSH initially dropped by 25% (P < 0.01) and 10% (P < 0.05), a gradual escape occurred during the DA infusion, followed by rebounds of 23% (P < 0.01) and 16% (P < 0.01), respectively. A brief rise in serum GH levels occurred with DA treatment, followed by a return to baseline. Subsequently, oscillatory spikes continued throughout the DA infusion but were significantly decreased (P < 0.01) after stopping DA. Thus, DA administration initially produced a reduction in serum PRL, TSH, LH, and FSH while stimulating GH release. PRL and TSH showed a sustained inhibition, whereas LH and FSH progressively escaped after a lesser degree of suppression by DA. The rebound after DA withdrawal probably reflected the discharge of hormone synthesized and stored during DA administration. The inverse relationship between the nadir of inhibition and the peak rebound values (r = 0.92) supports this hypothesis. Clearly, the patterns of serum LH, FSH, and GH values differ with acute and chronic DA administration. These differences are of potential importance in interpreting dopaminergic influences on anterior pituitary function.
* This work was supported in part by NIH Grant AM-11727 and General Clinical Research Center Grant RR-43. This study was published in abstract form in Clin Res 27: 21 A, 1979.
Recipient of a Medical Research Council of Canada Fellowship.
Received January 21, 1980.
This article has been cited by other articles:
 |
|
 |
|
  P. Kok, F. Roelfsema, M. Frolich, J. van Pelt, A. E. Meinders, and H. Pijl Short-Term Treatment with Bromocriptine Improves Impaired Circadian Growth Hormone Secretion in Obese Premenopausal Women J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3455 - 3461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Gordon, D. H. Rowitch, M. L. Mitchell, and I. S. Kohane Topical Iodine and Neonatal Hypothyroidism Arch Pediatr Adolesc Med, December 1, 1995; 149(12): 1336 - 1339. [Abstract] [PDF]
|
|
|
|
 |
|
 M. I. Surks, I. J. Chopra, C. N. Mariash, J. T. Nicoloff, and D. H. Solomon American Thyroid Association Guidelines for Use of Laboratory Tests in Thyroid Disorders JAMA, March 16, 1990; 263(11): 1529 - 1532. [Abstract] [PDF]
|
|
|
|
 |
|
 D. A. Ehrmann, M. Weinberg, and D. H. Same Limitations to the Use of a Sensitive Assay for Serum Thyrotropin in the Assessment of Thyroid Status Arch Intern Med, February 1, 1989; 149(2): 369 - 372. [Abstract] [PDF]
|
|
|
|
 |
|
 I. N. Ferrier, E. C. Johnstone, T. J. Crow, and I. Rincon-Rodriguez Anterior Pituitary Hormone Secretion in Chronic Schizophrenics: Responses to Administration of Hypothalamic Releasing Hormones Arch Gen Psychiatry, July 1, 1983; 40(7): 755 - 761. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
